570672
二甲基亚砜-d 6
anhydrous, 99.9 atom % D
别名:
DMSO-d6, 二甲基亚砜-d6, 氘代二甲亚砜
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
(CD3)2SO
化学文摘社编号:
分子量:
84.17
UNSPSC Code:
12142201
NACRES:
NA.21
PubChem Substance ID:
EC Number:
218-617-0
Beilstein/REAXYS Number:
1237248
MDL number:
Isotopic purity:
99.9 atom % D
Assay:
≥99.00%
Mass shift:
M+6
Form:
liquid
产品名称
二甲基亚砜-d 6, anhydrous, 99.9 atom % D
InChI key
IAZDPXIOMUYVGZ-WFGJKAKNSA-N
InChI
1S/C2H6OS/c1-4(2)3/h1-2H3/i1D3,2D3
SMILES string
[2H]C([2H])([2H])S(=O)C([2H])([2H])[2H]
grade
anhydrous
vapor pressure
0.42 mmHg ( 20 °C)
isotopic purity
99.9 atom % D
assay
≥99.00%
form
liquid
autoignition temp.
573 °F
expl. lim.
42 %
technique(s)
NMR: suitable
impurities
<50 ppm water
refractive index
n20/D 1.476 (lit.)
bp
189 °C (lit.)
mp
20.2 °C (lit.)
density
1.190 g/mL at 25 °C (lit.)
mass shift
M+6
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
氘代二甲亚砜 可用作 1H和 13C NMR实验的NMR溶剂。
General description
氘代二甲亚砜 （DMSO-d6）是一种氘代NMR溶剂。它经过光解离可产生CD3 自由基光产物，该产物已经过红外二极管激光吸收光谱法分析。已使用光碎片平移光谱法检测DMSO-d6 在193nm处的解离动力学。
Other Notes
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
190.4 °F
flash_point_c
88 °C
Silvana Cartaxo da Costa Urtiga et al.
Carbohydrate polymers, 250, 116929-116929 (2020-10-15)
Xylan extracted from corn cobs was used to produce mesalamine-loaded xylan microparticles (XMP5-ASA) by cross-linking polymerization using a non-hazardous cross-linking agent. The microparticles were characterized by thermal analysis (DSC/TG), X-ray diffraction (XRD), Infrared spectroscopy (FTIR-ATR) and scanning electron microscopy (SEM).
Unraveling the dissociation of dimethyl sulfoxide following absorption at 193 nm.
Blank DA, et al.
J. Chem. Phys. , 106(2), 539-550 (1997)
Solution forms of an antitumor cyclic hexapeptide, RA-VII in dimethyl sulfoxide-d6 from nuclear magnetic resonance studies.
Itokawa H, et al.
Chemical & Pharmaceutical Bulletin, 40(4), 1050-1052 (1992)
Diode laser measurements of CD3 quantum yields and internal energy for the dissociation of dimethyl sulfoxide-d6.
Rudolph RN, et al.
J. Chem. Phys. , 106(4), 1346-1352 (1997)
Luís Novo et al.
Molecular pharmaceutics, 12(1), 150-161 (2014-11-11)
The applicability of small interfering RNA (siRNA) in future therapies depends on the availability of safe and efficient carrier systems. Ideally, siRNA delivery requires a system that is stable in the circulation but upon specific uptake into target cells can
相关内容
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持